← Back to Search

Beta Blocker

Timolol 0.5% Gel Forming Solution (GFS) for Infantile Hemangiomas (TOUCH Trial)

Phase 2
Waitlist Available
Led By Vikash S. Oza, MD
Research Sponsored by Children's Hospital of Philadelphia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 3 months
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group

Summary

The purpose of this study is to determine whether Timolol 0.5% Gel Forming Solution is safe and effective in promoting wound healing of infantile ulcerated hemangiomas compared with standard conservative management with topical antibiotic.

Eligible Conditions
  • Infantile Hemangiomas

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Evaluate number of participants with changes in Glucose levels after drug is applied
Evaluate number of participants with changes in Heart Rate after drug is applied
Body Weight Changes
+4 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Timolol 0.5% Gel Forming Solution (GFS)Experimental Treatment1 Intervention
Half of enrolled subjects will receive topical Timolol
Group II: Mupirocin 2% ointmentActive Control1 Intervention
Half of enrolled subjects will receive Mupirocin

Find a Location

Who is running the clinical trial?

Children's Hospital of PhiladelphiaLead Sponsor
729 Previous Clinical Trials
8,470,311 Total Patients Enrolled
Society for Pediatric DermatologyOTHER
8 Previous Clinical Trials
490 Total Patients Enrolled
1 Trials studying Infantile Hemangiomas
118 Patients Enrolled for Infantile Hemangiomas
Vikash S. Oza, MDPrincipal InvestigatorChildren's Hospital of Philadelphia, Attending Physician
~0 spots leftby Nov 2025